Please try another search
For the nine months ended 30 September 2021, DicernaPharmaceuticals Inc revenues increased 23% to $151.9M. Netloss increased 15% to $87.9M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing increase of 29% to$50.7M (expense), Labor & Related Expenses in R&D increaseof 24% to $58.7M (expense).
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Revenue | 62.95 | 41.34 | 47.6 | 40.96 |
Gross Profit | ||||
Operating Income | -20.27 | -40.24 | -29.11 | -31.65 |
Net Income | -17.07 | -40.81 | -29.96 | -36.59 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Assets | 772.06 | 838.49 | 683.41 | 707.85 |
Total Liabilities | 664.4 | 727.42 | 557.01 | 570.09 |
Total Equity | 107.66 | 111.07 | 126.4 | 137.75 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 68.35 | 132.14 | -26.7 | 175.11 |
Cash From Investing Activities | -49.84 | -55.72 | 52.89 | -258.86 |
Cash From Financing Activities | 20.48 | 18.03 | 6.16 | 59.42 |
Net Change in Cash | 38.99 | 94.44 | 32.34 | -24.32 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review